Infigratinib Before Surgery for the Treatment of Upper Tract Urothelial Cancer
Stopped Drug manufacturer made the business decision to cease all infigratinib oncology research in the US and withdrew the IND
Conditions
- Renal Pelvis and Ureter Urothelial Carcinoma
Interventions
- DRUG: Infigratinib
- OTHER: Quality-of-Life Assessment
- OTHER: Questionnaire Administration
- PROCEDURE: Surgical Procedure
Sponsor
M.D. Anderson Cancer Center
Collaborators